Related Experiment Video
Updated: May 27, 2025
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and CD155/TIGIT Pathway
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is the deadliest major cancer and has a profoundly immunosuppressive tumor microenvironment (TME). Previous studies have shown that inhibition of the E1 enzyme, which catalyzes the small ubiquitin-like modifiers (SUMO), with the small molecule TAK-981, can reprogram the TME to enhance immune activation and suppress tumor growth. We found that the CD-155/TIGIT pathway, a key regulator of immune evasion in PDAC, is influenced by SUMOylation. We hypothesized that the combination of SUMO E1 and TIGIT inhibition would synergistically induce anti-tumor immune effects. We used a clinically relevant orthotopic mouse model that consistently develops liver metastases to study this combination therapy alone and in the perioperative setting with surgical resection. The combination of SUMO E1 and TIGIT inhibition significantly prolonged survival. Complete responders exhibited protective immunity and enhanced T cell reactivity to model-specific alloantigens. Complementary immune analyses of resected tumors demonstrated that combination therapy more significantly reduces the abundance of regulatory FOXP3+CD4+ T cells than each monotherapy alone. The findings suggest that SUMO E1 inhibition enhances antibody-mediated elimination of Tregs through innate immune cells, potentially by activation of type I interferon responses. Our results highlight a mechanism to enhance the efficacy of anti-TIGIT therapy.
Brief Summary:
SUMOylation is a post-translational modification process critical for cancer. Inhibition of SUMOylation can improve the sensitivity of pancreatic cancer to immune checkpoint inhibition.
Insights
Combining SUMO E1 inhibition with TIGIT blockade shows promise for pancreatic cancer. This approach reprograms the tumor microenvironment, enhancing anti-tumor immunity and improving survival in preclinical models.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Pancreatic ductal adenocarcinoma (PDAC) presents a significant challenge due to its immunosuppressive tumor microenvironment (TME).
- SUMOylation, a critical post-translational modification, influences cancer progression and immune evasion.
- The CD-155/TIGIT pathway is a key mediator of immune evasion in PDAC.
Purpose of the Study:
- To investigate the synergistic effects of inhibiting SUMO E1 and the TIGIT pathway in a preclinical model of PDAC.
- To evaluate the combination therapy in both monotherapy and perioperative settings with surgical resection.
- To elucidate the underlying mechanisms of enhanced anti-tumor immunity.
Main Methods:
- Utilized a clinically relevant orthotopic mouse model of PDAC with liver metastases.
- Administered combination therapy of SUMO E1 inhibitor (TAK-981) and TIGIT blockade.
- Conducted perioperative treatment in conjunction with surgical resection.
- Performed comprehensive immune analyses, including T cell reactivity and regulatory T cell (Treg) quantification.
Main Results:
- The combination therapy significantly prolonged survival in the PDAC mouse model.
- Complete responders demonstrated protective immunity and enhanced T cell responses.
- Combination therapy led to a greater reduction in regulatory FOXP3+CD4+ T cells compared to monotherapies.
- SUMO E1 inhibition appeared to enhance antibody-mediated Treg elimination via innate immune cells, potentially through type I interferon responses.
Conclusions:
- Combined SUMO E1 and TIGIT inhibition offers a synergistic strategy to enhance anti-tumor immunity in PDAC.
- This combination effectively reduces regulatory T cells and improves survival.
- The findings provide a mechanistic rationale for enhancing anti-TIGIT therapy efficacy through SUMOylation inhibition.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
10:11Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
Related Concept Videos
01:27Tumor Immunotherapy
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...